138 reports of this reaction
1.3% of all ENTECAVIR ANHYDROUS reports
#20 most reported adverse reaction
PATHOGEN RESISTANCE is the #20 most commonly reported adverse reaction for ENTECAVIR ANHYDROUS, manufactured by Amneal Pharmaceuticals LLC. There are 138 FDA adverse event reports linking ENTECAVIR ANHYDROUS to PATHOGEN RESISTANCE. This represents approximately 1.3% of all 10,248 adverse event reports for this drug.
Patients taking ENTECAVIR ANHYDROUS who experience pathogen resistance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PATHOGEN RESISTANCE is a less commonly reported adverse event for ENTECAVIR ANHYDROUS, but still significant enough to appear in the safety profile.
In addition to pathogen resistance, the following adverse reactions have been reported for ENTECAVIR ANHYDROUS:
The following drugs have also been linked to pathogen resistance in FDA adverse event reports:
PATHOGEN RESISTANCE has been reported as an adverse event in 138 FDA reports for ENTECAVIR ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
PATHOGEN RESISTANCE accounts for approximately 1.3% of all adverse event reports for ENTECAVIR ANHYDROUS, making it a notable side effect.
If you experience pathogen resistance while taking ENTECAVIR ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.